{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T16:54:54Z","timestamp":1783875294836,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Metastatic carcinoma of the paranasal sinuses in lung cancer is an extremely uncommon condition. We report here a 57-year-old female patient with epidermal growth factor receptor (EGFR)-positive stage IV non-small cell lung cancer (NSCLC) with multiple bone metastases. After resistance to second- and third-generation EGFR-tyrosine kinase inhibitors (TKIs), the patient presented with headache accompanied by progressively enlarging lesions of the nasal cavity on CT scan. Further endoscopic sinus neoplasmectomy confirmed sinus metastasis of lung adenocarcinoma. Although subsequent chemotherapy and immunotherapy were both administered, the disease continued to progress, and the patient passed away 21\u2009months after diagnosis. Combined with real-time dynamic next-generation sequencing (NGS) during the different generations of EGFR-TKI treatments and dynamic tumour microenvironment analysis, we discussed the clinical manifestations of sinus metastasis and the molecular biology and tumour immune microenvironment changes after resistance to the second-and third- generation of EGFR-TKI therapy.<\/jats:p>","DOI":"10.3389\/fmed.2023.1323222","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T05:27:50Z","timestamp":1704950870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Sinus metastasis of lung adenocarcinoma: a case report"],"prefix":"10.3389","volume":"10","author":[{"given":"Mingyuan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12885-016-2169-5","article-title":"Distribution and prognosis of uncommon metastases from non-small cell lung Cancer","volume":"16","author":"Niu","year":"2016","journal-title":"BMC Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"710","DOI":"10.21037\/tlcr.2019.06.02","article-title":"Immunotherapy in Egfr mutant non-small cell lung Cancer: when, who and how?","volume":"8","author":"Bruno","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic Egfr-mutated non-small cell lung Cancer a Meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"Ca-a Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/cco.0000000000000703","article-title":"Lung Cancer in China: current and Prospect","volume":"33","author":"Wu","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.46234\/ccdcw2022.036","article-title":"Burden of disease due to Cancer-China, 2000-2019","volume":"4","author":"Fan","year":"2022","journal-title":"China Cdc Weekly"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung Cancer","volume":"86","author":"Riihimaeki","year":"2014","journal-title":"Lung Cancer"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/s2213-2600(18)30264-9","article-title":"Detection of Egfr mutations in plasma circulating tumour DNA as a selection criterion for first-line Gefitinib treatment in patients with advanced lung adenocarcinoma (benefit): a phase 2, single-arm, multicentre clinical trial","volume":"6","author":"Wang","year":"2018","journal-title":"Lancet Respir Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/jcm9041047","article-title":"Concomitant Tp53 mutation confers worse prognosis in Egfr-mutated non-small cell lung Cancer patients treated with Tkis","volume":"9","author":"Canale","year":"2020","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3760\/cma.j.cn112152-20191118-00746","article-title":"Treatment of adenoid cystic carcinoma of sphenoid sinus with lung metastasis by Arotinib: a case report","volume":"42","author":"Xu","year":"2020","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/s0266-4356(02)00131-6","article-title":"Bronchogenic metastasis involving the frontal sinus and masquerading as a Pott's puffy tumour: a diagnostic pitfall","volume":"40","author":"Clarkson","year":"2002","journal-title":"Br J Oral Maxillofac Surg"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.otohns.2004.09.070","article-title":"Frontal sinus tumor as the first sign of adenocarcinoma of the lung","volume":"132","author":"Rombaux","year":"2005","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/JTO.0b013e3181949f30","article-title":"Nasion swelling as the presenting symptom of lung adenocarcinoma","volume":"4","author":"Huang","year":"2009","journal-title":"J Thorac Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.16066\/j.1672-7002.2010.03.020","article-title":"Metastases to maxillary sinus of lung Cancer","volume":"17","author":"Ma","year":"2010","journal-title":"Chin Arch Otolaryngol Head Neck Surg"},{"key":"ref15","first-page":"910","article-title":"A case report of nasal cavity and maxillary sinus metastasis of lung Cancer","volume":"40","author":"Luo","year":"2013","journal-title":"Cancer Res Prevent Treat"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.31768\/2312-8852.2015.37(3):231-232","article-title":"Unusual metastases of lung Cancer: Bulbus oculi and maxillary sinus","volume":"37","author":"Ates","year":"2015","journal-title":"Exp Oncol"},{"key":"ref17","first-page":"74","article-title":"Distant metastases to maxillary sinus from an unknown lung Adenocarcin Oma: a cases report","volume":"30","author":"Liang","year":"2016","journal-title":"Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.12998\/wjcc.v10.i17.5869","article-title":"Lung Adenocarcinoma Metastasis to Paranasal Sinus: A Case Report","volume":"10","author":"Li","year":"2022","journal-title":"World J Clin Cases"},{"key":"ref19","first-page":"50","article-title":"Misdiagnosis of lung Cancer with Sinonasal metastasis as the first symptom: a case report","volume":"48","author":"Xu","year":"2021","journal-title":"Chin J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ebiom.2020.102990","article-title":"Specific Tp53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma","volume":"60","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung Cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.18.00107","article-title":"Influence of Tp53 mutation on survival in patients with advanced Egfr-mutant non-small-cell lung Cancer","volume":"2018","author":"Aggarwal","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jtho.2022.02.011","article-title":"Concurrent Tp53 mutations facilitate resistance evolution in Egfr-mutant lung adenocarcinoma","volume":"17","author":"Vokes","year":"2022","journal-title":"J Thorac Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.21037\/jtd-20-1630","article-title":"Impact of Egfr amplification on survival of patients with Egfr exon 20 insertion-positive non-small cell lung Cancer","volume":"12","author":"Gao","year":"2020","journal-title":"J Thorac Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.Ccr-15-0560","article-title":"The allelic context of the C797s mutation acquired upon treatment with third-generation Egfr inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin Cancer Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jtho.2020.04.014","article-title":"Effective treatment of lung adenocarcinoma harboring Egfr-activating mutation, T790m, and Cis-C797s triple mutations by Brigatinib and Cetuximab combination therapy","volume":"15","author":"Wang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with Egfr T790m-positive lung Cancer and acquired resistance to Osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/cas.13919","article-title":"Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations","volume":"110","author":"Miyauchi","year":"2019","journal-title":"Cancer Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/cas.13860","article-title":"Mutational activation of the epidermal growth factor receptor Down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung Cancer","volume":"110","author":"Watanabe","year":"2019","journal-title":"Cancer Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"eaav3937","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of Egfr improves responsiveness to Pd-1 blockade in Egfr-mutated non-small cell lung Cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Sci Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"658690","DOI":"10.3389\/fonc.2021.658690","article-title":"Low infiltration of Cd8+Pd-L1+T cells and M2 macrophages predicts improved clinical outcomes after immune checkpoint inhibitor therapy in non-small cell lung carcinoma","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e002356","DOI":"10.1136\/jitc-2021-002356","article-title":"Massive Pd-L1 and Cd8 double positive tils characterize an immunosuppressive microenvironment with high mutational burden in lung Cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-019-0760-3","article-title":"Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications","volume":"12","author":"Lin","year":"2019","journal-title":"J Hematol Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1002\/cncr.32876","article-title":"Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung Cancer: analysis of over 8000 cases","volume":"126","author":"Mack","year":"2020","journal-title":"Cancer"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"6901","DOI":"10.2147\/cmar.S329900","article-title":"Comparison of different Egfr gene mutation status in patients with metastatic non-small lung Cancer after first-line Egfr-Tkis therapy and analyzing its relationship with efficacy and prognosis","volume":"13","author":"Yuan","year":"2021","journal-title":"Cancer Manag Res"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1323222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T05:27:59Z","timestamp":1704950879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1323222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":35,"alternative-id":["10.3389\/fmed.2023.1323222"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1323222","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"article-number":"1323222"}}